Skip to main content

Table 3 Medications according to blood pressure control on admission and 30 days after BTK intervention

From: Impact of uncontrolled hypertension on 12-month clinical outcomes following below-the-knee arteries (BTK) interventions in patients with critical limb ischemia

Variable. n%

Total (n = 165 Pts) (n = 201 Limb) (n = 246 Lesion)

Controlled HTN (n = 53 Pts) (n = 66 Limb) (n = 90 Lesion)

Uncontrolled HTN (n = 112 Pts) (n = 135 Limb) (n = 156 Lesion)

P Value

In-hospital medications

    

Aspirin

165 (100.0)

53 (100.0)

112 (100.0)

1.000

Clopidogrel

152 (92.1)

48 (90.5)

104 (92.8)

0.758

Cilostazol

81 (49)

28 (52.8)

53 (47.3)

0.617

Warfarin

12 (7.2)

3 (5.6)

9 (8.0)

0.753

Sarpogrelate

61 (36.9)

21 (39.6)

40 (35.7)

0.730

Diuretics

41 (24.8)

11 (20.7)

30 (26.7)

0.446

ß-blockers

58 (35.1)

21 (39.6)

37 (33)

0.485

Ca-blockers

84 (50.9)

29 (54.7)

55 (49.1)

0.510

ACE-inhibitors

36 (21.8)

10 (18.8)

26 (23.2)

0.687

ARBs

73 (44.2)

25 (47.1)

48 (42.8)

0.618

Statins

114 (69)

39 (73.5)

75 (66.9)

0.472

30 days medications

    

Aspirin

155 (93.9)

52 (98.1)

103 (91.9)

0.170

Clopidogrel

140 (84.8)

48 (90.5)

92 (82.1)

0.244

Cilostazol

54 (32.7)

20 (37.7)

34 (30.3)

0.377

Warfarin

10 (6.0)

3 (5.6)

7 (6.2)

1.000

Sarpogrelate

60 (36.3)

21 (39.6)

39 (34.8)

0.605

  1. Values are mean ± SD (range). BTK indicates Below-the-knee, HTN hypertension, Pts patients, ACE angiotensin converting enzyme, ARB angiotensin II receptor blocker